Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Ecnoglutide improves glycaemic control in type 2 diabetes
Last updated August 15, 2026
Key finding
HbA1c decreased by 1.96% (95% CI -2.18 to -1.73)
Ecnoglutide demonstrated significant improvements in glycaemic control in adults with type 2 diabetes inadequately managed by diet and exercise.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Ecnoglutide demonstrated significant improvements in glycaemic control in adults with type 2 diabetes inadequately managed by diet and exercise.
Clinical relevance
These findings are clinically significant as they suggest that Ecnoglutide could be an effective treatment option for adults with type 2 diabetes who struggle to control their blood sugar levels through diet and exercise alone. Improved glycaemic control can lead to better long-term health outcomes and reduce the risk of diabetes-related complications.
Keep in mind
Limited sample size may affect generalizability. Short duration of the study may not reflect long-term effects. Potential for unmeasured confounders influencing results.
Published in
Journal Reference
Publication details and source links for this paper.
Dalong Z, Weimin W, Guoyu T, et al. Ecnoglutide, a cAMP-biased GLP-1 analogue, improves glycaemic control in adults with type 2 diabetes. Nature Communications. 2026;17:1420. doi:10.1038/s41467-025-68165-7
Main Effects
HbA1c decreased by 1.96% (95% CI -2.18 to -1.73)
HbA1c decreased by 2.43% (95% CI -2.65 to -2.20)
Fasting plasma glucose decreased by 3.32 mmol/L (95% CI -3.68 to -2.97)
Body weight decreased by 3.21 kg (95% CI -3.84 to -2.58)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Ecnoglutide 1.2 mg, Pemvidutide 1.2 mg and Body weight, Fasting Plasma Glucose (FPG), HbA1c.
This study contributes evidence to
Primary intervention
Ecnoglutide 1.2 mg
Primary outcomes
- Body weight
- Fasting Plasma Glucose (FPG)
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
6
Evidence pairs
1865
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Fasting Blood Glucose
matched_outcome
Related evidence
Evidence topic
Glycemic Control
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Ecnoglutide 1.2 mg → Fasting Plasma Glucose (FPG)
Ecnoglutide 1.2 mg → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Pemvidutide 1.2 mg → Fasting Plasma Glucose (FPG)
Pemvidutide 1.2 mg → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Ecnoglutide reduced HbA1c levels by up to 2.43%.
- Fasting plasma glucose decreased by 3.32 mmol/L.
- Body weight decreased by an average of 3.21 kg.
Who this applies to
- Adults with type 2 diabetes inadequately controlled by diet and exercise.
- Participants who are seeking additional pharmacological interventions.
Keep in Mind
- Results may not apply to populations outside the study sample.
- Ecnoglutide's long-term safety and efficacy are not yet established.
- Further research is needed to confirm findings in diverse populations.
Between the Lines
- Limited sample size may affect generalizability.
- Short duration of the study may not reflect long-term effects.
- Potential for unmeasured confounders influencing results.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Pemvidutide 1.2 mg and Body Weight, Ecnoglutide 1.2 mg and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Pemvidutide 1.2 mg → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceMedications
Ecnoglutide 1.2 mg → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Ecnoglutide 1.2 mg → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
Pemvidutide 1.2 mg Evidence Hub
All studies on Pemvidutide 1.2 mg
2 studies
intervention_hubContributes to Pemvidutide 1.2 mg evidence base.
Ecnoglutide 1.2 mg Evidence Hub
All studies on Ecnoglutide 1.2 mg
1 studies
intervention_hubContributes to Ecnoglutide 1.2 mg evidence base.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
1 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Pemvidutide 1.2 mg and Body weight
Intervention: Pemvidutide 1.2 mgOutcome: Body weight
2 results
All studies on Ecnoglutide 1.2 mg and Body weight
Intervention: Ecnoglutide 1.2 mgOutcome: Body weight
1 results
All studies on Pemvidutide 1.2 mg
Intervention: Pemvidutide 1.2 mg
2 results
All studies on Ecnoglutide 1.2 mg
Intervention: Ecnoglutide 1.2 mg
1 results
All studies measuring Body weight
Outcome: Body weight
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Pemvidutide 1.2 mg affect body weight?
Moderate Evidence
Pemvidutide 1.2 mg appears to affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Ecnoglutide 1.2 mg affect body weight?
Emerging Evidence
Ecnoglutide 1.2 mg appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Ecnoglutide 1.2 mg improve fasting plasma glucose (FPG)?
Emerging Evidence
Ecnoglutide 1.2 mg appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Ecnoglutide 1.2 mg lower HbA1c?
Emerging Evidence
Ecnoglutide 1.2 mg appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Exercise Improves Serum Albumin Levels in Women with Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesBariatric surgery improves glucose homeostasis in type 2 diabetes.CT-868 Improves Glycaemic Control in Type 2 Diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.